lunes, 23 de febrero de 2026

Gilead to buy Arcellx in nearly $8B deal The two companies were already partnered on a multiple myeloma CAR-T treatment

https://www.statnews.com/2026/02/23/gilead-arcellx-acquisition-car-t-multiple-myeloma/ By Adam FeuersteinFeb. 23, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

No hay comentarios: